Correct. They have already told investors that NICE evidence submission/approval is unlikely in 2026. Otherwise they would have submitted already so that reimbursement approval is more or less simultaneous.
And the fact that they are pivoting towards Direct and in licensed Roswell tech for new trials and then compassionate use for L in the US tells you that FDA submission for L is unlikely anytime soon. Certainly not happening in 2026. Take that to the bank!
This ain’t even getting to .50s again. In fact, I expect folks to be desperate to get out in the .20s next year as shares dip under .10 with extended dilution and delays. Just wait and watch!
Market Data 
Markets 
AI
